What is the average price target for REGENXBIO INC (RGNX) stock?
19 analysts have analysed RGNX and the average price target is 30.26 USD. This implies a price increase of 218.86% is expected in the next year compared to the current price of 9.49.
REGENXBIO INC (RGNX) Forecast, Price Target & Analyst Ratings
NASDAQ:RGNX • US75901B1070
Current stock price
9.49 USD
+0.3 (+3.26%)
At close:
9.67 USD
+0.18 (+1.9%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for REGENXBIO INC (RGNX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.37
- Revenue Estimate
- 26.848M
Price Target Details & History
Consensus Price Target and Range
Mean target
$30.26
Upside
+ 218.86%
From current price of $9.49 to mean target of $30.26, Based on 19 analyst forecasts
Low
$12.12
Median
$29.07
High
$52.50
Price Target Revisions
1 Month
-1.62%
3 Months
-9.47%
Price Target Summary
19 Wall Street analysts provided a forecast for the next 12 months for RGNX. The average price target is 30.26 USD. This implies a price increase of 218.86% is expected in the next year compared to the current price of 9.49.
The average price target has been revised downward by 9.47% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.21%
RGNX was analyzed by 19 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about RGNX.
In the previous month the buy percentage consensus was at a similar level.
RGNX was analyzed by 19 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-06 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-02-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-02-10 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2026-02-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-02-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-29 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-19 | Stifel | Maintains | Buy -> Buy |
| 2025-12-15 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-11-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-08 | Barclays | Maintains | Overweight -> Overweight |
| 2025-06-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-03-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-14 | Chardan Capital | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.37
- Revenue Estimate
- 26.848M
- Revenue Q2Q
- -69.84%
- EPS Q2Q
- -1,238.06%
- Number of Analysts
- 11
Next Earnings Revisions
Revenue (1 Month)
2.38%
Revenue (3 Months)
-66.05%
EPS (1 Month)
-8.75%
EPS (3 Months)
-323.70%
Next Earnings Summary
RGNX is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -1.37 USD and the consensus revenue estimate is 26.85M USD.
The next earnings revenue estimate has been revised downward by 66.05% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 90.242M -19.93% | 83.328M -7.66% | 170.441M 104.54% | 257.72M 51.21% | 306.9M 19.08% | 500.35M 63.03% | 680.36M 35.98% | 880.98M 29.49% | 1.129B 28.15% | 1.201B 6.38% | 1.232B 2.58% | |
| EBITDA YoY % growth | -250.808M -0.32% | -214.13M 14.62% | -145.483M 32.06% | -120.52M 17.16% | -115.805M 3.91% | -59.778M 48.38% | 102.07M 270.75% | 217.38M 112.97% | 246.63M 13.46% | 286.07M 15.99% | 294.72M 3.02% | |
| EBIT YoY % growth | -268.128M -1.99% | -230.345M 14.09% | -161.098M 30.06% | -136.01M 15.57% | -107.674M 20.83% | -13.632M 87.34% | 59.696M 537.92% | 272.51M 356.50% | 374M 37.24% | 419.04M 12.04% | 424.92M 1.40% | |
| Operating Margin | -297.12% | -276.43% | -94.52% | -52.77% | -35.08% | -2.72% | 8.77% | 30.93% | 33.13% | 34.89% | 34.49% | |
| EPS YoY % growth | -6.03 7.23% | -4.56 24.38% | -3.76 17.54% | -2.52 32.92% | -2.87 -13.86% | -1.82 36.57% | 0.58 131.91% | 3.94 577.19% | 8.55 117.23% | 9.39 9.78% | 9.20 -2.01% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.37 -1,238.06% | 0.28 120.37% | -1.23 -2.47% | -0.78 39.90% | -1.09 20.46% | -0.92 -426.61% | -0.11 91.29% | -1.16 -48.17% | -0.09 91.55% | -0.13 85.56% | -0.12 -14.29% | -0.13 88.55% |
| Revenue Q2Q % growth | 26.848M -69.84% | 127.75M 498.11% | 37.533M 26.23% | 60.105M 98.12% | 35.588M 32.55% | 51.398M -59.77% | 92.198M 145.65% | 42.478M -29.33% | 85.099M 139.12% | 88.159M 71.52% | 89.74M -2.67% | 95.962M 125.91% |
| EBITDA Q2Q % growth | -58.861M -466.00% | 35.893M 164.77% | -60.576M -48.96% | -64.938M -54.54% | -48.491M 17.62% | -43.982M -222.54% | -32.456M 46.42% | -24.817M 61.78% | -1.489M 96.93% | -3.101M 92.95% | -3.519M 89.16% | -3.233M 86.97% |
| EBIT Q2Q % growth | -65.408M -639.36% | 20.129M 131.81% | -59.567M -13.65% | -39.716M 31.09% | -49.72M 23.98% | -41.32M -305.28% | -872.1K 98.54% | -55.192M -38.97% | -5.528M 88.88% | -7.089M 82.84% | -7.487M -758.48% | -7.201M 86.95% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
14.86%
EPS Next 5 Year
24.96%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
40.44%
Revenue Next 5 Year
37.29%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
16.92%
EBIT Next 5 Year
28.18%
REGENXBIO INC / RGNX Forecast FAQ
What is the next earnings date for RGNX stock?
REGENXBIO INC (RGNX) will report earnings on 2026-05-06, after the market close.
What are the consensus estimates for REGENXBIO INC (RGNX) next earnings?
The consensus EPS estimate for the next earnings of REGENXBIO INC (RGNX) is -1.37 USD and the consensus revenue estimate is 26.85M USD.
How do analysts rate REGENXBIO INC (RGNX)?
The consensus rating for REGENXBIO INC (RGNX) is 84.2105 / 100 . This indicates that analysts generally have a positive outlook on the stock.